Table 3.

Outcome Median Overall Survival, Progression-Free Survival, Objective Response and Side Effects

Study	Abdel-Rahman et al13		Qin et al15		Gish et al14		Yeo et al16		Abou Alfa et al17		Mok et al18
Study arm	Sorafenib	Capecitabine	FOLFOX	Doxorubicin	Nolatrexed	Doxorubicin	Doxorubicin	PIAF	D+S	D+P	Nolatrexed	Doxorubicin
Progression-free survival	6m	4m	2.93m	1.77m	2.76m	2.3m	NS	NS	6m	2.7m	1.58m	1.55m
	p < 0.005, HR 2.708		p < 0.001, HR 0.62		p= 0.709				p= 0.006, HR: 0.45
Median overall survival	7.05m	5.07m	6.4m	4.79m	5.13m	7.43m	6.83m	8.67m	13.7m	6.5m	4.6m	3.4m
	p < 0.016, HR 2.36		p= 0.07, HR 0.8		p=0.0068, HR 0.753		p= 0.83, HR 0.97		p= 0.006, HR 0.49		p = 0.9843
Main adverse event	Hand and foot syndrome, gastrointestinal	Hyperbilirubinemia, gastrointestinal	Neutropenia Nausea ↑ AST anorexia	Alopecia ↑ AST Nausea	Stomatitis Vomiting Diarrhea Thrombocytopenia	Alopecia Neutropenia Anemia	Neutropenia Anemia Thrombocytopenia	Neutropenia Thrombocytopenia Hypokalemia	Leucopenia Hand & foot skin reaction Diarrhea Systolic dysfunction	Fatigue Neutropenia Diarrhea	Neutropenia Stomatitis Anemia vomiting	Neutropenia Anemia Alopecia
Partial response	3pts	1pt	15	5	NS	NS	9	19	2	0	0	0
Complete response	1pt	0	0	0	NS	NS	0	0	0	1	0	0
Response rate	14.5%	3%	8.15%	2.67%	1.4%	4%	10.5%	20.9%	4%	2%	0	0

Abbreviations: m, month; HR, hazard ratio; D+S, doxorubicin+sorafenib; D+P, doxorubicin+placebo; NS, not specified.